Join the Oncology Voice Network. Join for Free
Research Highlights In The News From ESMO
ESMO cancer treatment optimization NICHE-2 trial SWOG S1801 trial IPSOS trial oncology research

Research Highlights In The News From ESMO


Share This Article


Summary

  • The ESMO 2022 Congress took place in Paris in September 2022, with around 29,000 delegates, including 5,000 online participants.
  • The program featured a broad range of topics, including clinical trial results, translational studies, and health policy initiatives.
  • A key theme discussed was the optimization of treatment for patients with locally advanced, resectable cancers.
  • The phase II NICHE-2 trial showed that neoadjuvant treatment with ipilimumab plus nivolumab was safe and effective in non-metastatic mismatch repair-deficient colon cancer, with no disease recurrence after a median follow-up of 13 months.
  • The phase II SWOG S1801 trial demonstrated that neoadjuvant pembrolizumab improved event-free survival and overall survival in patients with stage IIIB–IV melanoma.
  • The phase III IPSOS trial found that atezolizumab extended overall survival and reduced adverse events in patients with non-small-cell lung cancer (NSCLC) without actionable driver alterations, compared to standard chemotherapy options.

In September 2022, the ESMO 2022 Congress was held in Paris, marking the return of a highly anticipated annual in-person event for the oncology community. The conference attracted 29,000 delegates, with approximately 5,000 joining the event online.

The congress featured a diverse program, carefully curated by the programme committee to include a wide range of topics such as clinical trial results, translational studies, and health policy initiatives. The three Presidential Symposia exemplified the variety of themes explored during the event, with a significant focus on optimizing treatment for patients with locally advanced, resectable cancers.

Click for Source Download PDF version
ESMO, cancer treatment optimization, NICHE-2 trial, SWOG S1801 trial, IPSOS trial, oncology research

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
OVN Avatar Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Article
Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers
OVN Avatar Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang

Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN